Prior to these transactions, on November 27, Sims acquired 14 shares at a price of $10.1 each, totaling $141. Following these acquisitions, Sims directly owns 283,285 shares of Eagle Capital Growth Fund, while his spouse indirectly holds an additional 11,389 shares. The filing notes that Sims disclaims beneficial ownership of the shares held by his spouse. InvestingPro analysis shows the fund maintains strong liquidity with a current ratio of 3.29 and has maintained dividend payments for 35 consecutive years. Unlock more insights and 3 additional ProTips with an InvestingPro subscription. InvestingPro analysis shows the fund maintains strong liquidity with a current ratio of 3.29 and has maintained dividend payments for 35 consecutive years. Unlock more insights and 3 additional ProTips with an InvestingPro subscription.
Prior to these transactions, on November 27, Sims acquired 14 shares at a price of $10.1 each, totaling $141. Following these acquisitions, Sims directly owns 283,285 shares of Eagle Capital Growth Fund, while his spouse indirectly holds an additional 11,389 shares. The filing notes that Sims disclaims beneficial ownership of the shares held by his spouse.
In other recent news, Grifols (BME:GRLS), a global healthcare company, has received FDA approval for its Fibrin Sealant (FS) for use in pediatric surgery in the United States. This product, aimed at controlling surgical bleeding, has demonstrated over 95% efficacy in achieving hemostasis within four minutes of application in pediatric patients, according to a successful phase 3b clinical trial. Marketed as VISTASEAL™ in the U.S. and Canada and VERASEAL™ in Europe, this biosurgery treatment is a collaboration between Grifols and Johnson & Johnson MedTech.
The product, now available in 18 countries, employs airless spray technology to rapidly form clots, a critical aspect in surgeries where bleeding is a potential issue. VISTASEAL™ is indicated as an adjunct to hemostasis for mild to moderate bleeding during surgery when conventional methods are ineffective or impractical, including in heparinized patients. However, it is not recommended for direct injection into the circulatory system or for severe arterial bleeding.
These developments underline Grifols' ongoing efforts to expand its portfolio with innovative healthcare solutions. As with any human blood product, it is important to note that there is a risk of transmitting infectious agents. The information in this article is based on a recent press release statement from Grifols.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.